Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.
Demirci
Umut
U
Department of Medical Oncology, Gazi University, Ankara, Turkey.
Coskun
Ugur
U
Erdem
Ozlem
O
Ozturk
Banu
B
Bilge Yilmaz
Isilay
I
Benekli
Mustafa
M
Buyukberber
Suleyman
S
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001706:Biopsy; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000473:pathology; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects; D012393:Rosacea / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012880:Skin Pigmentation / Q000187:drug effects; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001549:Benzamides; D006633:Histamine Antagonists; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib